The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
PersonGen’s LV009 takes the industry tally of clinical-stage projects to 14.
Mocertatug rezetecan is starting its first western pivotal trials.
The holiday period included Genmab’s discontinuation of acasunlimab.
Nenocorilant features among the latest industry projects newly into phase 1.
A deal with Jacobio is worth $100m up front.
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
